Synchron Raises $200M Series D for BCI Commercialization and Next-Gen Technology
Synchron announced it has secured $200 million in a Series D funding round to advance the commercialization of its brain-computer interface (BCI) system. The New York–based company intends to use the funds to accelerate the market launch of its Stentrode BCI and to develop a next-generation interface.
Funding and Development Plans
This latest financing brings Synchron’s total capital raised to $345 million. The company aims to speed up pivotal trials ahead of the Stentrode launch and expand its team of engineers, neuroscientists, and operators to drive innovation in BCI technology.
Cognitive AI and Engineering Expansion
Synchron is also growing its Cognitive AI division in New York to develop models capable of decoding brain signals in real time. Additionally, it has established a new engineering hub in San Diego focused on building advanced brain interfaces.
Investors and Participation
- Lead investor: Double Point Ventures
- Existing investors: ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, METIS
- New investors: Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, IQT
Unique Technology: The Stentrode Interface
Synchron describes Stentrode as the only BCI that captures brain signals via blood vessels, detecting motor intention through an endovascular approach.
The implant is placed on the surface of the motor cortex through the jugular vein, enabling it to detect motor signals from within the brain’s blood vessels.
Summary
Synchron’s substantial funding highlights its commitment to bringing innovative, minimally invasive brain-computer interfaces to market and advancing next-generation neurotechnology.